DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rilutek (Riluzole) - Summary



RILUTEK® (riluzole) is a member of the benzothiazole class.

RILUTEK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy.

See all Rilutek indications & dosage >>


Media Articles Related to Rilutek (Riluzole)

Targeting structure of enzyme has potential to treat amyotrophic lateral sclerosis
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.09.15]
Investigators from the School of Medicine at The University of Texas Health Science Center at San Antonio have determined the first high-resolution structure of an enzyme that, if partially...

New Lou Gehrig's disease study shows that blocking ALS mutation in the brain slowed disease initiation and progression
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.11.13]
Lou Gehrig's disease, also known as amyotrophic lateral sclerosis, or ALS, might damage muscle-controlling nerve cells in the brain earlier in the disease process than previously known, according to...

ACE Inhibitors to Prevent ALS?
Source: Medscape NeurologyHeadlines [2014.11.12]
In a new case-control study, ACE inhibitors, commonly used antihypertensive drugs, were associated with a significant reduction in the risk for amyotrophic lateral sclerosis.
Medscape Medical News

Small set of genes identified that are critical in aging and neurodegenerative disease
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.11.05]
Aging is the most significant and universal risk factor for developing neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's, Parkinson's and Huntington's diseases.

more news >>

Published Studies Related to Rilutek (Riluzole)

Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury. [2011.06]
The objectives of this study were to probe the contribution of spinal neuron persistent sodium conductances to reflex hyperexcitability in human chronic spinal cord injury... These results suggest that intrinsic spinal cellular excitability could be a target for managing chronic spinal cord injury hyperreflexia impairments without causing a significant loss in volitional strength.

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. [2010.05]
BACKGROUND: In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS). We aimed to confirm or disprove these findings by assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS... INTERPRETATION: We found no evidence that lithium in combination with riluzole slows progression of ALS more than riluzole alone. The time-to-event endpoint and use of prespecified interim analyses enabled a clear result to be obtained rapidly. This design should be considered for future trials testing the therapeutic efficacy of drugs that are easily accessible to people with ALS. FUNDING: National Institute of Neurological Disorders and Stroke, ALS Association, and ALS Society of Canada. Copyright 2010 Elsevier Ltd. All rights reserved.

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. [2010.03.09]
BACKGROUND: The pleiotropic effects of riluzole may antagonize common mechanisms underlying chronic cerebellar ataxia, a debilitating and untreatable consequence of various diseases... CONCLUSIONS: These findings indicate the potential effectiveness of riluzole as symptomatic therapy in diverse forms of cerebellar ataxia. Classification of evidence: This study provides Class I evidence that riluzole reduces, by at least 5 points, the ICARS score in patients with a wide range of disorders that cause cerebellar ataxia (risk difference 63.2%, 95% CI 33.5%-79.9%).

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. [2010.02]
The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit transient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD) aimed to (1) replicate the acute efficacy of single-dose intravenous (i.v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse; and (3) examine whether pretreatment with lamotrigine would attenuate ketamine's psychotomimetic effects and enhance its antidepressant activity.

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. [2010]
patients with ALS... INTERPRETATION: We found no evidence that lithium in combination with riluzole

more studies >>

Clinical Trials Related to Rilutek (Riluzole)

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Recruiting]
This phase I trial is studying the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with advanced solid tumors or melanoma. Riluzole may stop or slow the growth of tumor cells. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving riluzole together with sorafenib tosylate may kill more tumor cells

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression [Recruiting]

Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder [Recruiting]
Obsessive-compulsive disorder (OCD) affects 2-3% of the population and leads to a great deal of suffering. Many patients benefit from established treatments, the mainstay of which are cognitive behavioral therapy and a group of antidepressant medications known as serotonin reuptake inhibitors. However, 20-30% of patients get minimal benefit from these established therapeutic strategies. New avenues of treatment are urgently needed.

Existing medications for obsessive-compulsive disorder affect the neurotransmitters serotonin or dopamine; but increasing evidence suggests that functional disruptions of a different neurotransmitter, glutamate, may contribute to some cases of OCD. The investigators are therefore interested in using medications that target glutamate as novel treatment options for those OCD patients who do not benefit from established treatments.

One such medication is the drug riluzole, which is FDA approved for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, but may be of benefit to patients with psychiatric disorders due to its ability to moderate excessive glutamate. In preliminary studies, in which the investigators treated patients with riluzole (in addition to their established pharmacological regimen) in an open-label fashion (that is, without a placebo-treated control group), the investigators have found about 40-50% of patients to substantially improve over 2-3 months.

While immensely promising, these preliminary studies do not prove riluzole is truly a new beneficial medication for the treatment of OCD; a more rigorous placebo-controlled trial is needed for that purpose. The investigators are therefore now recruiting patients to participate in a double-blind, placebo-controlled trial of riluzole, added to whatever other OCD medications they are taking.

Riluzole Augmentation Pilot in Depression (RAPID) Trial [Recruiting]
The investigators are doing a research study to find out if riluzole, when taken along with a standard antidepressant (sertraline) can help people with major depression.

This research study will compare riluzole + sertraline to placebo + sertraline. The investigators hypothesize that adding riluzole will lead to a better antidepressant response, in less time, then sertraline alone.

A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD [Not yet recruiting]
This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.

more trials >>

Reports of Suspected Rilutek (Riluzole) Side Effects

Death (4)Pyrexia (3)Agranulocytosis (3)Respiratory Failure (3)Confusional State (2)Pulse Abnormal (2)Pallor (2)Hypokalaemia (2)OFF Label USE (2)Weight Increased (2)more >>

Page last updated: 2014-11-13

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014